Compare AbCellera Biologics Inc (ABCL) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Value Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Vanguard Value Index Fund ETF trades at $217.65. The key difference: Vanguard Value Index Fund ETF is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | VTV | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $220.51 |
52-Week Low | $2.78 | $175.51 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
VTV trades at $219.57 with a slight 0.18% daily gain, showing strong 2026 performance with a 16% year-to-date return. Technical indicators signal bullish momentum with moving averages strongly positive, while oscillators remain neutral. The ETF benefits from market rotation away from tech stocks toward value investments, with recent news highlighting its defensive positioning amid Fed policy uncertainty and AI bubble concerns.
VTV offers exposure to large-cap value stocks with minimal tech concentration, providing diversification benefits as markets shift from growth to value. Key risks include Fed rate hike sensitivity and macroeconomic volatility, though the ETF's low 0.03% expense ratio and value focus position it well for continued rotation trends. Analyst sentiment is mixed with some caution about limited upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
